{
  "abstract": "Induced pluripotent stem cell (iPSC)-based treatments have revolutionized regenerative medicine, yielding patient-specific renewable cells without raising ethical concerns related to the use of embryonic stem cells. In two decades, iPSC therapies have advanced from basic research to clinical trials and official approvals. Early research focused on autologous transplantation, exemplified by the 2014 retinal pigment epithelium (RPE) graft. Yet, personalized production obstacles prompted allogeneic schemes relying on HLA cell banks and immunomodified donor cells. Meanwhile, innovations such as chemical reprogramming have revitalized autologous strategies. Today, autologous and allogeneic iPSC therapies complement each other for distinct clinical demands. This review traces key field milestones and analyzes prospects and hurdles for next-generation iPSC therapies.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Anesthesiology and Perioperative Medicine, David Geffen School of Medicine, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Biology, University of California, Los Angeles, CA 90095, USA",
    "School of Basic Medical Sciences, MOE Engineering Research Center of Regenerative Medicine, State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center and the MOE Key Laboratory of Cell Proliferation and Differentiation, College of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100191, China",
    "Changping Laboratory, Beijing 102206, China"
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 4,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Anmin Wang"
    },
    {
      "affs": [
        0
      ],
      "name": "Yunpei Zhang"
    },
    {
      "affs": [
        1,
        2
      ],
      "name": "Hongkui Deng"
    },
    {
      "affs": [
        0
      ],
      "name": "Mingxia Gu"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/5mhehzt44td2v.bib",
  "cited_by": 0,
  "doi": "10.1016/j.xcrm.2026.102992",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13710136/",
  "id": "5mhehzt44td2v",
  "issns": [
    "2666-3791"
  ],
  "landing_url": "https://doi.org/10.1016/j.xcrm.2026.102992",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Review"
    ],
    [
      "openalex",
      "1312|Pluripotent Stem Cells Research"
    ]
  ],
  "openalex": "W7203703364",
  "pdf_url": null,
  "pmcid": "PMC13710136",
  "pmid": "42612639",
  "published": "2026-08-18",
  "publisher": "Elsevier",
  "ris": "https://research.draconitic.com/paper/5mhehzt44td2v.ris",
  "sources": [
    {
      "first_seen": "2026-10-31T12:21:09Z",
      "native_id": "PMC13710136",
      "source": "pmc",
      "url": "https://doi.org/10.1016/j.xcrm.2026.102992"
    }
  ],
  "subjects": [
    {
      "field": "biochemistry",
      "origin": "openalex:1312|Pluripotent Stem Cells Research",
      "subfield": "molecular-biology"
    }
  ],
  "title": "The evolution of iPSC-based cell therapy across autologous and allogeneic pathways",
  "title_text": "The evolution of iPSC-based cell therapy across autologous and allogeneic pathways",
  "type": "peer-reviewed",
  "updated_at": "2026-10-31T12:21:09Z",
  "url": "https://research.draconitic.com/paper/5mhehzt44td2v",
  "venue": "Cell Reports Medicine",
  "versions": []
}